• Home
  • » 
  • Reports
  • » 
  • Contract Manufacturing in Pharmaceutical Industry

Contract Manufacturing in Pharmaceutical Industry

  • Lowest Price Guaranteed From USD 2,199

  • Published
    February 2015

  • Pages
    319

  • View Count
    10556

  • Buy Now

Example Insights

An updated edition is available at the following link 

View 2nd edition

  1. North America and Europe are the predominant regions where majority of the production facilities of CMOs are located. Out of 509 CMOs we studied, 189 have presence in multiple locations in the US. In Europe, the other major hub for CMOs, Germany, Italy and the UK have presence of 58, 37 and 32 CMOs respectively. Companies have also gradually moved their focus to developing countries in order to take advantage of the relatively lower costs.
  2. The market is well distributed between API manufacturers and FDF manufacturers. Within FDF contract manufacturing, solid dose compounds currently dominate the market. However, future growth is likely to be driven by injectables dose manufacturing primarily due to increased focus on complex disease areas and the growing trend of self-administration.
  3. In terms of analysis by scale of operation, majority of the CMOs have the capability to operate on clinical as well as commercial scale. Out of 394 CMOs evaluated for this exercise, 340 CMOs have the provision for both clinical and commercial stage manufacturing.
  4. High potency and biopharmaceuticals manufacturing represent a major growth opportunity for CMOs. Owing to the capital intensive nature of the business and complex manufacturing requirements, CMOs have become the preferred manufacturing partners for majority of the pharmaceutical clients.
  5. The intense competition in the marketplace is driving CMOs to explore innovation aspects such as eClinical systems, cloud based computing and risk monitoring tools to create differentiation. Specifically, for biopharmaceuticals manufacturing, CMOs have started utilizing novel bio-processing services and technologies such as single use bioreactors.
  6. With respect to the market size, we have estimated the API and FDF contract manufacturing to be worth USD 35 Billion currently. Driven by the increasing trend of outsourcing, we expect the market to grow at an annualized rate of 8.3%.

Report Description

Amongst the increasing financial pressures and the need to reduce cost and improve efficiencies, the pharmaceutical industry has witnessed a paradigm shift from vertically integrated business model to a network of suppliers. As such, contract manufacturing has evolved as one of the integral components of the pharmaceutical market. Started initially as a one-off activity, contract manufacturing has evolved into a dynamic business model; currently most prevalent in manufacturing, outsourcing is steadily spanning the entire pharmaceutical value chain. With CMOs now offering the entire multitude of services from design and discovery to final packaging, the concept of ‘one stop shop’ service provider is gradually gaining pace.

The market has witnessed several major trends that have governed the evolution of contract manufacturing over the past few years. One of the most significant changes in the outsourcing space is the emergence of strategic contract manufacturing. The conventional model of contract manufacturing involved a vendor-customer equation. However, phasing out that traditional concept, contract manufacturers nowadays believe in entering in strategic alliances with CMO partners with the objective of cutting down production cost and enhancing product pipelines.

The contract manufacturing market, broadly categorized into API manufacturing and FDF manufacturing, has witnessed significant growth in the past several years driven by factors such as cost efficiency, technical expertise, and increased time efficiency. The current marketplace is inundated with numerous established as well as emerging CMOs, with a diverse array of service offerings and scale of operation. Despite being faced with challenges such as heavy competition and lack of funding, contract manufacturing in itself characterizes a huge opportunity for the pharmaceutical sector. Inevitably, substantial growth prospects lie ahead for pharmaceutical contract manufacturers; CMOs who will be able to provide certain differentiating elements targeting diverse customer groups stand to benefit the most in this competitive landscape.

 

Scope of the Report

The "Contract Manufacturing in Pharmaceutical Industry, 2015 - 2025" report provides an extensive study of the rapidly growing pharmaceutical contract manufacturing market. With pharmaceutical and biotechnology industry striving to minimize costs and maximize profits, outsourcing has emerged as an ever increasing trend. The study presents an in-depth analysis of a diverse set of CMOs on some of the key parameters such as type of business operation, scale of operation, packaging form, geographical location and range of services. In addition, it captures some of the key growth areas which will likely present tremendous opportunities for CMOs and ensure an accelerated pace of growth. Some of the potential growth areas include biopharmaceutical and high potency manufacturing. Specifically, in these markets, complex manufacturing requirements and capital intensive nature of the business make outsourcing an attractive option.

The report assesses some of the key drivers that have governed the evolution of contract manufacturing market over the past several years along with an elaborate discussion on the future trends that will shape the market in the coming years. One of the focus areas of this study is to estimate size of the future opportunity in the pharmaceutical contract manufacturing market over the next decade, segmented on the basis of business operations and key regions. 

In addition to some of the well-known benefits and a promising outlook, the study also highlights considerable challenges currently prevalent in the market. Examples include quality concerns, cultural differences and lack of transparency in the manufacturing process. Nevertheless, these challenges are paving the way for new strategies and technological improvements, which will indeed be advantageous in the long run.

The base year for the report is 2014; the report provides market forecasts for the period 2015 - 2025. The research, analysis and insights presented in this report is backed by a deep understanding of key insights gathered both from secondary and primary research.

Contents

Chapter 2  provides an executive summary of the insights captured in our research. The summary offers a high level view on where the pharmaceutical contract manufacturing market is headed in the mid-long term.

Chapter 3  provides the definition of contract manufacturing and a general introduction on the role of a third party service provider in the pharmaceutical industry. We have also explained, in detail, the range of services offered by CMOs and challenges involved in contract manufacturing.

Chapter 4  highlights the key growth drivers and restraints of the contract manufacturing market. The chapter also talks about various models of contract manufacturing and some of the important trends that have shaped the market in the past several years.

Chapter 5  details contract manufacturing space specifically in China and India, providing information on regulatory framework, growth drivers, challenges and emerging opportunities in each of these countries. The chapter also provides a high-level view on production capabilities of some of the leading Chinese and Indian CMOs in the market.

Chapter 6  provides a detailed analysis of a diverse set of established and emerging pharmaceutical CMOs active in the market. An in-depth review including regional distribution, analysis by type of business operation, scale of operation, packaging and services has been covered in this chapter.

Chapter 7  focuses on biopharmaceutical contract manufacturing, a major growth opportunity for CMOs. The chapter provides an in-depth analysis specifically for biopharmaceutical CMOs on some of the key parameters including geographical location, scale of operation, types of expression systems, types of biologics manufactured, types of bioreactors and fermentation capacity.

Chapter 8  presents the detailed forecast for both API and FDF contract manufacturing. Due to the uncertain nature of the market, we have presented three different growth tracks outlined as conservative, base and optimistic scenarios.

Chapter 9  includes profiles of some of the key players in the pharmaceutical contract manufacturing market. Each company profile includes information such as geographical presence, financial performance, manufacturing capabilities, investments, partnerships and future outlook.

Chapter 10  highlights some of the important trends that will likely govern the growth and evolution of contract manufacturing market in the future.

Chapter 11  is a collection of transcripts of interviews conducted during the course of this study. Examples of companies interviewed include Corden Pharma, Helsinn, CiVentiChem and Novasep.

Chapter 12  summarizes the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.

Chapter 13  is an appendix which provides tabulated data and numbers for all the figures provided in the report.

Chapter 14  is an appendix which provides a list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. EXECUTIVE SUMMARY
 
3. INTRODUCTION
3.1. Context and Background
3.2. Contract Manufacturing: Definition
3.3. Services Performed by CMOs
3.4. Top Factors for CMO Selection
3.5. Risk Factors and Challenges in Contract Manufacturing
 
4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Growth Drivers
4.2.1. Divestment of Non-core Businesses
4.2.2. Efforts to Cut Production Costs
4.2.3. Technical Expertise
4.2.4. Shift Towards Emerging Markets
4.2.5. Biopharmaceuticals Contract Manufacturing
 
4.3. Restraints
4.3.1. Overcapacity
4.3.2. Price Pressures
4.3.3. Lack of Funding
4.3.4. Heavy Competition
 
4.4. Contract Manufacturing Models
4.4.1. Shift from Tactical to Strategic
4.4.2. Integrated End-to-End Business Model
4.4.3. Intimate Long-Term Alliances
4.4.4. Flexible Short-Term Partnership
4.4.5. Innovation Driven Contract Manufacturing
4.4.5.1. Cloud based Systems Gaining Importance
4.5. Trends
 
5. EMERGING REGIONS IN THE CMO MARKET
5.1. Chapter Overview
5.2. China
5.2.1. Regulatory Scenario in China
5.2.2. Challenges for Chinese CMO Market
5.2.3. Emerging Opportunities
5.2.4. Leading Contract Manufacturers in China
5.2.4.1. Asymchem Laboratories
5.2.4.2. Beijing Second Pharmaceutical
5.2.4.3. Chongqing Huapont Pharmaceutical
5.2.4.4. Porton Fine Chemicals
5.2.4.5. Tianjin Pharmaceutical
5.2.4.6. Venturepharm Laboratories
5.2.4.7. WuXiAppTec
5.2.4.8. ZhejianHisun Pharma
5.2.4.9. Zhejiang Huahai Pharmaceutical
 
5.3. India
5.3.1. Evolution of Indian Contract Manufacturing Model
5.3.2. Regulatory Scenario in India
5.3.3. Emerging Opportunities
5.3.4. Challenges for the Indian CMO Market
5.3.5. Leading Contract Manufacturers in India
5.3.5.1. Aurobindo Pharma
5.3.5.2. Divis Laboratories
5.3.5.3. Piramal Healthcare Pharma Solutions
5.3.5.4. Dr. Reddy’s Laboratories
5.3.5.5. Dishman Pharma
 
6. COMPETITIVE LANDSCAPE
6.1. Chapter Overview
6.2. Analysis by Business Operations
6.3. Analysis by Scale of Operations
6.4. Analysis by Type of FDF
6.5. Analysis by Pharma Form Packaging
6.6. Analysis by Services
6.7. Analysis by Geography
 
7. BIOPHARMACEUTICAL CONTRACT MANUFACTURING
7.1. Chapter Overview
7.2. Manufacturing of Biopharmaceuticals
7.2.1. Microbial Expression Systems
7.2.1.1. Bacterial Protein Expression System
7.2.1.2. Yeast Protein Expression System
7.2.2. Mammalian Protein Expression System
7.2.3. Insect Protein Expression System
7.2.4. Plant Protein Expression System
7.3. Evolution of Biopharmaceutical Contract Manufacturing
7.4. Biopharmaceutical CMOs: Analysis by Region
7.5. Biopharmaceutical CMOs: Analysis by Scale of Operation
7.6. Biopharmaceutical CMOs: Analysis by Capability
7.6.1. Distribution by Type of Biologic Molecule
7.6.2. Distribution by Expression Systems
7.7. Biopharmaceutical CMOs: Type of Bioreactor
 
8. MARKET SIZE AND FORECAST
8.1. Forecast Methodology
8.2. Key Drivers
8.3. API Manufacturing Market, 2014 - 2025
8.4. FDF Contract Manufacturing Market, 2014 - 2025
8.4.1. FDF Contract Manufacturing Market: Distribution by Type, 2015, 2020 and 2025
8.5. Overall Contract Manufacturing Market, 2014 - 2025
8.6. Contract Manufacturing Market: Regional View
 
9. COMPANY PROFILES
9.1. Chapter Overview
9.2. Patheon
9.2.1. Company Overview
9.2.2. Financial Performance
9.2.3. Manufacturing Capabilities
9.2.3.1. Manufacturing Locations
9.2.3.2. Technical Solutions
9.2.4. Partnerships
9.2.5. Approvals
9.2.6. Expansions
9.2.7. Future Outlook
 
9.3. Catalent
9.3.1. Company Overview
9.3.2. Financial Performance
9.3.3. Manufacturing Capabilities
9.3.3.1. Manufacturing Locations
9.3.3.2. Technical Solutions
9.3.4. Partnerships
9.3.5. Approvals
9.3.6. Expansions
9.3.6.1. Geographical Expansions
9.3.6.2. Capability Expansions
9.3.6.3. Capacity Expansions
9.3.7. Future Outlook
 
9.4. Fareva
9.4.1. Company Overview
9.4.2. Manufacturing Capabilities
9.4.2.1. Manufacturing Locations
9.4.3. Partnerships
9.4.4. Approvals
9.4.5. Expansions
9.4.5.1. Geographical Expansions
9.4.5.2. Capability Expansions
9.4.5.3. Capacity Expansions
9.4.6. Future Outlook
9.4.7. Excella GmbH, a Part of Fareva
 
9.5. Aenova
9.5.1. Company Overview
9.5.2. Manufacturing Capabilities
9.5.2.1. Dosage Forms
9.5.2.2. Manufacturing Locations
9.5.3. Approvals
9.5.4. Expansions
9.5.4.1. Geographic Expansions
9.5.4.2. Capability Expansions
9.5.4.3. Capacity Expansions
9.5.5. Future Outlook
9.5.6. Haupt Pharma
 
9.6. Lonza
9.6.1. Company Overview
9.6.2. Financial Performance
9.6.3. Manufacturing Capabilities
9.6.3.1. Manufacturing Locations
9.6.3.2. Technical Solutions
9.6.4. Partnerships
9.6.5. Expansions
9.6.5.1. Capability Expansions
9.6.5.2. Capacity Expansions
9.6.6. Future Outlook
 
9.7. Evonik
9.7.1. Company Overview
9.7.2. Financial Performance
9.7.3. Manufacturing Capabilities
9.7.3.1. Manufacturing Locations
9.7.4. Expansions
9.7.4.1. Geographic Expansions
9.7.4.2. Capability Expansions
9.7.4.3. Capacity Expansion
9.7.5. Future Outlook
 
9.8. Boehringer Ingelheim BioXcellence
9.8.1. Company Overview
9.8.2. Financial Performance
9.8.3. Manufacturing Capabilities
9.8.3.1. Manufacturing Locations
9.8.4. Partnerships
9.8.5. Expansions
9.8.5.1. Geographical Expansions
9.8.5.2. Capacity Expansions
9.8.6. Future Outlook
 
9.9. Aesica
9.9.1. Company Overview
9.9.2. Manufacturing Capabilities
9.9.2.1. Manufacturing Locations
9.9.2.2. Technical Solutions
9.9.3. Partnerships
9.9.4. Approvals
9.9.5. Expansions
9.9.5.1. Geographical Expansions
9.9.5.2. Capability Expansions
9.9.5.3. Capacity Expansions
9.9.6. Future Outlook
 
9.10. Famar
9.10.1. Company Overview
9.10.2. Manufacturing Capabilities
9.10.2.1. Manufacturing Locations
9.10.3. Partnerships
9.10.4. Expansions
9.10.4.1. Capacity Expansions
9.10.5. Future Outlook
 
9.11. Recipharm
9.11.1. Company Overview
9.11.2. Financial Performance
9.11.3. Manufacturing Capabilities
9.11.3.1. Manufacturing Locations
9.11.4. Partnerships
9.11.5. Approvals
9.11.6. Expansions
9.11.6.1. Geographical Expansions
9.11.6.2. Capability Expansions
9.11.6.3. Capacity Expansion
9.11.7. Future Outlook
 
9.12. Jubilant
9.12.1. Company Overview
9.12.2. Financial Performance
9.12.3. Manufacturing Capabilities
9.12.3.1. Manufacturing Locations
9.12.4. Partnerships
9.12.5. Future Outlook
 
10. FUTURE OF THE CMO MARKET
10.1. Chapter Overview
10.2. Focus on Emerging Markets
10.3. Shift Towards an Integrated Business Model
10.4. Biologics to Expand the Global CMO Market
10.5. Innovation to Drive Growth
10.6. Information Sharing and Collaboration
10.7. High Potency and Cytotoxic Drugs Manufacturing: Emerging Focus
10.8. Growing Demand to Spur Investment Activity
10.9. Case Study: Contract Manufacturing in Gene Therapy
 
11. INTERVIEW TRANSCRIPTS
11.1. Kevin Daley, Market Director (Pharmaceuticals), Novasep Synthesis
11.2. Roberto Margarita, Business Development Director, Corden Pharma
11.3. Allison Vavala, Senior Manager (Business Development), Helsinn
11.4. BhaskarVenepalli, President and CEO, CiVentiChem
 
12. CONCLUSION
12.1. Contract Manufacturing in Pharma: An Ever Increasing Trend
12.2. The Competitive Market to Witness an Accelerated Growth
12.3. Differentiation Strategy to Pave Way for Sustenance in the Market
12.4. Concluding Remarks
 
13. APPENDIX 1: TABULATED DATA
 
14. APPENDIX 2: LIST OF COMPANIES

List of Figures

Figure 2.1 Range of Contract Manufacturing Services: Example CMOs
Figure 3.1  Roles of a Third Party Service Provider in Pharmaceutical Industry
Figure 3.2  Outsourcing across the Pharmaceutical Value Chain
Figure 3.3  CMOs: Range of Services
Figure 5.1  Chinese CMO Market: Growth Drivers
Figure 5.2  Indian CMO Market: Growth Drivers
Figure 6.1  Extent of Outsourcing in Pharmaceutical Operations
Figure 6.2  Pharmaceutical Contract Manufacturing Landscape
Figure 6.3  CMOs: Distribution by Business Operations
Figure 6.4  CMOs: Distribution by Scale of Operation
Figure 6.5  CMOs: Distribution by Type of Dosage Forms
Figure 6.6  Types of Pharmaceutical Packaging Forms
Figure 6.7  CMOs: Distribution by Packaging Form
Figure 6.8  CMOs: Regional Distribution
Figure 7.1  Types of Expression Systems
Figure 7.2  Biopharmaceutical CMOs: Geographical Location
Figure 7.3  Biopharmaceutical CMOs: Regional Distribution
Figure 7.4  Biopharmaceutical CMOs: Distribution by Scale of Operation
Figure 7.5  Biopharmaceutical CMOs: Distribution by Type of Biologic Molecule
Figure 7.6  Biopharmaceutical CMOs: Distribution by Expression Systems
Figure 7.7  Single Use Bioreactors: Advantages and Disadvantages
Figure 8.1  Extent of Outsourcing: API and FDF Manufacturing, 2014 - 2025
Figure 8.2  API Manufacturing Market, 2014 – 2025: Base Scenario (USD billion)
Figure 8.3  FDF Manufacturing Market, 2014 – 2025: Base Scenario (USD billion)
Figure 8.4  FDF Contract Manufacturing Market: Distribution by Type, 2015, 2020 and 2025
Figure 8.5  Overall Contract Manufacturing Market, 2014 – 2025: Base Scenario (USD billion)
Figure 8.6  Contract Manufacturing Market: Regional Distribution, 2015, 2020 and 2025
Figure 9.1  Patheon: Revenues, 2009 – 2013 (USD million)
Figure 9.2  Patheon: Revenues by Business Divisions, 2013 (USD million)
Figure 9.3  Patheon: Revenue Break-up for CMO, 2013 (USD million, Percentage)
Figure 9.4  Catalent: Revenues, 2010 – 2014 (USD million)
Figure 9.5  Catalent: Revenues by Business Divisions, 2014 (USD million)
Figure 9.6  Lonza: Revenues, 2010 – 2014 (USD million)
Figure 9.7  Lonza: Revenues by Business Divisions, FY 2014 (CHF million)
Figure 9.8  Lonza: Potency Classification System
Figure 9.9  Evonik: Revenues, 2009 – 2013 (USD million)
Figure 9.10  Evonik: Revenues by Business Divisions, 2013 (EUR million)
Figure 9.11  Boehringer Ingelheim: Revenues, 2009 – 2013 (EUR million)
Figure 9.12  Boehringer Ingelheim: Revenues by Business Divisions, 2013 (EUR million)
Figure 9.13  Recipharm: Revenues, 2009 – 2013 (SEK million)
Figure 9.14  Recipharm: Revenues by Business Divisions, 2013 (SEK million)
Figure 9.15  Jubilant: Revenues by Business Divisions, FY 2014 (INR million)
Figure 10.1  Contract Manufacturing in Gene Therapy: By Capability
Figure 10.2  Contract Manufacturing in Gene Therapy: By Location
Figure 12.1  Pharmaceutical Contract Manufacturing: Key Drivers
Figure 12.2  API and FDF Contract Manufacturing Market (USD billion) Forecast: 2015, 2020 and 2024

List of Tables

Table 5.1  Asymchem Laboratories: Manufacturing Facilities
Table 5.2  Porton Fine Chemicals: Manufacturing Facilities and R&D Centers
Table 5.3  Venturepharm Laboratories: Holdings and Related Companies
Table 5.4  Dr. Reddy’s Laboratories: Manufacturing Facilities
Table 5.5  Dishman Pharma: Business Units
Table 6.1  CMOs: Analysis by Business Operations
Table 6.2  CMOs: Analysis by Scale of Operation
Table 6.3  CMOs: Analysis by Type of FDF
Table 6.4  CMOs: Analysis by Packaging Forms
Table 6.5  CMOs: Range of Services
Table 7.1  Biopharmaceutical CMOs: Scale of Operation
Table 7.2  Biopharmaceutical CMOs: Type of Biologics
Table 7.3  Biopharmaceutical CMOs: Analysis by Expression Systems
Table 7.4  Biopharmaceutical CMOs: Analysis by Type of Bioreactor
Table 9.1  Patheon: Capacity for Sterile Formulations Filling
Table 9.2  Patheon: Facilities
Table 9.3  Patheon: Additional Agreements, 2012-2014
Table 9.4  Catalent: Manufacturing and Laboratory Facilities
Table 9.5  Fareva: Manufacturing and Laboratory Facilities
Table 9.6 Aenova: Manufacturing Locations
Table 9.7  Lonza: Custom Development and Custom Manufacturing Sites
Table 9.8  Evonik: Facilities Sites and their Functions
Table 9.9  BioXcellence: Facilities and their Functions
Table 9.10  Aesica: Facility Sites and their Functions
Table 9.11  Famar: Facility Sites and their Functions
Table 9.12  Recipharm: Facility sites and their Functions
Table 9.13  Jubilant: Facility sites and their functions
Table 10.1  HPAPI CMO Investments, 2006-2014
Table 10.2  Contract Manufactures in Gene Therapy
Table 13.1  Extent of Outsourcing in Pharmaceutical Operations
Table 13.2  CMOs: Analysis by Business Operation, Scale and Type of FDF
Table 13.3  CMOs: Distribution by Business Operations
Table 13.4  CMOs: Distribution by Scale of Operation
Table 13.5  CMOs: Distribution by FDF Dosage Forms
Table 13.6  CMOs: Analysis by Packaging Form
Table 13.7  CMOs: Distribution by Packaging Form
Table 13.8  CMOs: Range of Services
Table 13.9  CMOs: Regional distribution
Table 13.10 Biopharmaceutical CMOs: Regional Distribution
Table 13.11  Biopharmaceutical CMOs: Distribution by Scale of Operation
Table 13.12  Biopharmaceutical CMOs: Distribution by Type of Biologic Molecule
Table 13.13  Biopharmaceutical CMOs: Distribution by Expression Systems
Table 13.14  Biopharmaceutical CMOs: Analysis by Type of Bioreactor
Table 13.15  Extent of Outsourcing: API and FDF Manufacturing, 2014 – 2025
Table 13.16  API Manufacturing Market, 2014 – 2025: Base Scenario (USD Billion)
Table 13.17  API Manufacturing Market, 2014 – 2025: Conservative Scenario (USD Billion)
Table 13.18  API Manufacturing Market, 2014 – 2025: Optimistic Scenario (USD Billion)
Table 13.19  FDF Manufacturing Market, 2014 – 2025: Base Scenario (USD Billion)
Table 13.20  FDF Manufacturing Market, 2014 – 2025: Conservative Scenario (USD Billion)
Table 13.21  FDF Manufacturing Market, 2014 – 2025: Optimistic Scenario (USD Billion)
Table 13.22  FDF Contract Manufacturing Market: Distribution by Type, 2015, 2020 and 2025
Table 13.23  Overall Contract Manufacturing Market, 2014 – 2025: Base Scenario (USD Billion)
Table 13.24  Overall Contract Manufacturing Market, 2014 – 2025: Conservative Scenario (USD Billion)
Table 13.25  Overall Contract Manufacturing Market, 2014 – 2025: Optimistic Scenario (USD Billion)
Table 13.26  Contract Manufacturing Market: Regional Distribution, 2015, 2020 and 2015
Table 13.27  Patheon: Revenues, 2009 - 2013 (USD million)
Table 13.28  Patheon: Revenues by Business Divisions, 2013 (USD million)
Table 13.29  Patheon: CMO Revenue Distribution, 2013 (USD million)
Table 13.30  Catalent: Revenues, 2010-2013 (USD million)
Table 13.31  Catalent: Revenues by Business Divisions, 2014 (USD million)
Table 13.32  Lonza: Revenues, 2010 - 2014 (CHF million)
Table 13.33  Lonza: Revenues by Business Divisions, 2013 (CHF million)
Table 13.34  Evonik: Revenues, 2009 - 2013 (EUR million)
Table 13.35  Evonik: Revenues by Business Divisions, 2013 (EUR million)
Table 13.36  Boehringer Ingelheim: Revenues, 2009 - 2013 (EUR million)
Table 13.37  Boehringer Ingelheim: Revenues by Business Divisions, 2013 (EUR million)
Table 13.38  Recipharm: Revenues, 2009 - 2013 (SEK million)
Table 13.39  Recipharm: Revenues by Business Divisions, 2013 (SEK million)
Table 13.40  Jubilant: Revenues by Business Divisions, 2013 (INR million)
Table 13.41  Contract Manufacturing in Gene Therapy: By Capability
Table 13.42  Contract Manufacturing in Gene Therapy: By Location

Listed Companies

The following companies have been mentioned in this report.

  1. 3M Drug Delivery Systems
  2. 3P Biopharmaceuticals
  3. A & Z Pharmaceutical
  4. AAIPharma Services
  5. Aarti CRAMS (division of Aarti Industries)
  6. Aarti Drugs  
  7. AbbVie 
  8. ABL, Inc.
  9. Accra Pac
  10. Accucaps Industries 
  11. Acino AG
  12. AcsDobfar Spa
  13. AdAlta
  14. Adamas Pharmaceuticals
  15. Adhesives Research 
  16. Aegerion
  17. Aenova
  18. AERAS
  19. Aesica Pharmaceuticals Limited
  20. Affinity Life Sciences, Inc.
  21. Afton Scientific Corporation
  22. Agennix
  23. Agno Pharma
  24. Ajinomoto Althea
  25. Akorn India Private Limited (Subsidiary of Akorn)
  26. Akums Drugs and Pharmaceutical Ltd.
  27. Aland (Jiangsu) Nutraceutical Co., Ltd.
  28. Aldevron
  29. Alkermes
  30. All Chem Laboratories
  31. Allergy Laboratories
  32. Almac Pharma 
  33. Alpax Pharmaceuticals
  34. Alphora Research 
  35. Alps Pharmaceutical 
  36. Amanta Healthcare
  37. Amatsi
  38. Ambiopharm
  39. Amdipharm
  40. American Antibiotics
  41. American Peptide Company
  42. Ami Drugs and Speciality Chemicals
  43. Amoli Organics 
  44. Ampac Fine Chemicals 
  45. AMRI  Inc.
  46. AMW GmbH
  47. AMYRA Biotech
  48. Angelini Pharmaceuticals (ACRAF)
  49. Anhui Biochem United Pharmaceutical Co., Ltd.
  50. Ankur Drugs and Pharma Ltd.
  51. AnqiuLu'an Pharmaceutical 
  52. Apexigen
  53. API Polpharma
  54. Apicore Pharmaceuticals (Subsidiary of Apicore US LLC)
  55. Apiscent Labs
  56. APL Sweden
  57. Apotex Fermentation 
  58. Aptuit
  59. Arbro Pharmaceuticals
  60. Arch Pharmalabs
  61. Arevipharma GmbH
  62. Arvincare
  63. Asahi Glass Company, Ltd.
  64. Asahi Kasei Finechem
  65. Aspen Bad Oldesloe GmbH
  66. Astimex Pharma
  67. AstraZeneca
  68. Asymchem Laboratories 
  69. Athera Biotechnologies
  70. Atra Pharmaceuticals Ltd.
  71. Aurobindo Pharma 
  72. AustarPharma
  73. Austin Pharma(Subsidiary of Cerilliant Corporation)
  74. AutekBio, Inc.
  75. Avalanche Biotechnologies
  76. Avid Bioservices, Inc.
  77. Avra Laboratories 
  78. Avyukt Pharmaceuticals
  79. B. Braun Medical 
  80. Bachem
  81. Banner Pharmacaps
  82. Batavia Bioservices
  83. Bausch & Lomb Incorporated
  84. Bavarian Nordic GmbH
  85. Baxil Pharma Ltd.
  86. Baxter BioPharma Solutions
  87. BCN Peptides SA
  88. BeiGene Co., Ltd.
  89. Beijing second Pharmaceutical Co., Ltd.
  90. Belcher Pharmaceuticals, LLC
  91. Beltapharm SPA
  92. Ben Venue Laboratories (Subsidiary of Boehringer Ingelheim)
  93. Beximco Pharmaceuticals Ltd.
  94. Bharat Biotech
  95. BIBITEC GmbH
  96. Binex Co. Ltd.
  97. Bio Elpida
  98. BioferS.p.A
  99. Biomay AG
  100. BIOMEVA GmbH
  101. Bionorica SE
  102. Bio-Pharm, Inc.
  103. Biopharmaceutical Development Program - Frederick National Laboratory  for Cancer Research (FNLCR) 
  104. BioReliance
  105. BioSynergy
  106. Biotechpharma UAB
  107. Biotika
  108. Biovectra Inc
  109. Biovian Ltd.
  110. BioVolutions
  111. BioWa, Inc.
  112. Bluepharma
  113. Boehringer Ingelheim BioXcellence
  114. Bristol-Myers Squibb
  115. Broad Pharmaceutical Co., Ltd.
  116. C & O Pharmaceutical technology Limited (Subsidiary of Shionogi & Co.,  Ltd)
  117. Cadila Pharmaceuticals Limited
  118. Calyx Chemicals & Pharmaceuticals Limited
  119. Cambrex 
  120. Capsugel
  121. Catalent 
  122. Celladon
  123. Celonic AG
  124. Cenexi
  125. Centaur Pharmaceuticals
  126. Center for Biocatalysis and Bioprocessing, The University of Iowa
  127. Century Pharmaceuticals Limited
  128. Cerbios Pharma 
  129. Cevec Pharmaceuticals
  130. CF Pharma Ltd.
  131. Chartwell Pharmaceuticals llc
  132. ChemCon GmbH
  133. ChemPacific Corporation
  134. ChemPartner
  135. Cherokee Pharmaceuticals LLC
  136. ChifengArker Pharmaceutical Technology Co. Ltd.
  137. China Chemical & Pharmaceutical Co., Ltd.
  138. Chiral Biosciences Ltd.
  139. Chongqing Huapont Pharmaceutical
  140. Chunghwa Chemical Synthesis & Biotech Co., Ltd.
  141. Cingulate Therapeutics
  142. CironPharma
  143. Cispharma Inc.
  144. CiVentiChem, LLC
  145. CMC Biologics
  146. CMIC CMO ASHIKAGA Co., Ltd.
  147. Coating Place Inc
  148. Cobra Biologics
  149. Cody Laboratories (Subsidiary of Lannett Company)
  150. Cognate BioServices
  151. Coldstream Laboratories, Inc.
  152. Concord Biotech Limited
  153. Confab Laboratories Inc.
  154. Contract Coating Inc.
  155. Contract Pharmacal Corporation
  156. Cook Pharmica LLC
  157. Cooper Pharma Ltd.
  158. Corden Pharma
  159. CoreRx Inc
  160. Corium International, Inc.
  161. Corvette Pharmaceutical Services Group
  162. Cris Pharma
  163. Crown Laboratories
  164. Crucell
  165. CTC Bio
  166. CTC Clinical Trial Consultants AB
  167. CTX Lifesciences Private Limited
  168. Custom Pharmaceutical Services (CPS), Dr. Reddy's Laboratories 
  169. Cytovance Biologics, Inc.
  170. Daiichi Fine Chemical Co., Ltd.
  171. Daito Pharmaceutical Co.,Ltd.
  172. Dalton Pharma Services
  173. Delavau LLC
  174. Delmar Chemicals Inc.
  175. Delpharm
  176. Dental Technologies, Inc.
  177. Development Center for Biotechnology, Taiwan
  178. Dipharma Francis S.r.l.
  179. Dishman Contract Researchand Manufacturing Services (CRAMS)
  180. Divi's Laboratories Limited
  181. DM Bio (Dong-A meiji)
  182. Dottikon Exclusive Synthesis AG
  183. Douglas Manufacturing Limited
  184. Dow Corning Corporation
  185. DPT Laboratories, Ltd.
  186. DPx Holdings
  187. DSM Pharmaceutical Products
  188. DuoCort
  189. Dupen Laboratories Pvt. Ltd.
  190. Dwarkesh Pharmaceuticals Pvt. Ltd.
  191. Ei Inc.
  192. EirGen Pharma Ltd
  193. Elan plc
  194. Eli Lilly
  195. Elite Laboratories, Inc.
  196. Embio Limited
  197. Emcure Pharmaceuticals
  198. Emergent Biosolutions
  199. Enaltec Labs 
  200. Encap Drug Delivery
  201. Enrich pharma
  202. Epic Pharma, LLC
  203. Eriochem S.A.
  204. ErregierreSpA
  205. EsteveQuimica
  206. Ethypharm
  207. Euro Vital Pharma GmbH & Co. KG
  208. Eurogentec Biologics
  209. Euticals
  210. Evonik Industries
  211. Excella GmbH
  212. Excelvision
  213. Exela Pharma Sciences
  214. F.I.S. FabbricaItalianaSintetici
  215. Famar
  216. Famy Care Limited
  217. Fareva
  218. Farmabios
  219. Farmaka.s
  220. Farmhispania, S.A.
  221. Fermic
  222. Fermion Oy
  223. Ferndale Laboratories (Part of Ferndale Pharma Group)
  224. Fertin Pharma A/S
  225. Finecure Pharmaceuticals Ltd.
  226. Flamel Technologies
  227. Flamingo Pharmaceuticals
  228. FlammaS.p.A.
  229. Fleming Laboratories Limited
  230. Florida Biologix®
  231. Fluid Energy Processing and Equipment Co
  232. Fresenius Kabi
  233. Fujifilm Diosynth Biotechnologies
  234. Fujimoto Chemicals Co., Ltd. Kinraku Plant
  235. Fujirebio Europe B.V. (previously Innogenetics)
  236. Future Pak LTD.
  237. G&W Laboratories 
  238. Gallus BioPharmaceuticals
  239. Genmab A/S
  240. Gland Pharma Limited
  241. Glatt GmbH
  242. GlaxoSmithKline Biopharmaceuticals
  243. Glenmark Pharmaceuticals Limited
  244. Global Harvest Pharma
  245. Glochem Industries Limited
  246. Glycotope Group
  247. Goodwin Biotechnology, Inc.
  248. Gordon Laboratories, Inc.
  249. GP Pharm
  250. Grand River Aseptic Manufacturing Inc.
  251. Granules Omnichem JV
  252. Grindeks
  253. Groupe PARIMA Inc.
  254. Guangzhou Baiyunshan Pharmaceutical Co., Ltd.
  255. Guardian Drug Company
  256. Hainan Poly Pharm
  257. Halo Pharmaceutical Inc
  258. Hanford Pharmaceuticals
  259. Hangzhou Hysen Pharma Co., Ltd.
  260. Hangzhou Imaginechem
  261. Haupt Pharma
  262. Health Biotech Limited
  263. Healthy Life Pharma Pvt. Ltd.
  264. Helios Pharma
  265. Helsinn Advanced Synthesis SA
  266. Hetero Drugs Limited
  267. Hikal Limited
  268. HolopackVerpackungstechnik GmbH
  269. HonsonPharmatech group, Ltd.
  270. Hospira One 2 One
  271. Hovione
  272. Hritik Chemical Pvt. Ltd.
  273. Hubei Biocause Pharmaceutical Co., Ltd
  274. HUIYU Pharmaceutical
  275. Hyglos GmbH
  276. ICROM S.p.A.
  277. IDT Australia Limited
  278. IDT Biologika GmbH
  279. IGI Labs, Inc.
  280. IMMUNE Pharmaceutical
  281. ImmuneMed, IncEclipse
  282. Immunetep
  283. Ind Swift Laboratories Limited
  284. Indena
  285. Index Ventures LLP
  286. Indoco Remedies Limited
  287. INFA Group
  288. Inno Biologics Sdn. Bhd.
  289. InnovaCaptab
  290. Innovent Biologics, Inc.
  291. Intas Pharmaceuticals
  292. IRIX Manufacturing Inc.
  293. Irvine Pharmaceutical Services
  294. Isochem (Subsidiary of Aurelius AG)
  295. Isofol Medical
  296. J.B. Chemicals & Pharmaceuticals Ltd.
  297. Johnson&Johnson
  298. Jubilant Life Sciences
  299. KBI BioPharma, Inc.
  300. Kekule Pharma Limited
  301. Kemwell Biopharma Private Limited
  302. Kilitch Drugs Ltd.
  303. Kongo Chemical Co., Ltd. Head Plant
  304. Korten
  305. Krebs Biochemicals& Industries Ltd
  306. Laurus Labs
  307. Legochem Biosciences
  308. LFB Biomanufacturing
  309. Lipogen
  310. LOBA FeinchemieGmbh
  311. Logos pharma
  312. Long Pharmaceuticals, LLC
  313. Lonza 
  314. LSNE
  315. LTS LohmannTherapie-Systeme AG
  316. Luitpold Pharmaceuticals, Inc.
  317. Lusomedicamenta
  318. Lyne Laboratories, Inc.
  319. Lyra Laboratories
  320. Mabion
  321. Macfarlan Smith Limited
  322. Macleods Pharmaceuticals Limited, Baddi
  323. Madras Pharmaceuticals
  324. MakcurLaboratoies Ltd.
  325. Malladi Drugs & Pharmaceuticals Limited
  326. Mass Biologics
  327. McGuff Pharmaceuticals Inc.
  328. MDC Pharmaceuticals Ltd.
  329. Medicago
  330. Medical Products Laboratories, Inc.
  331. Medichem S.A.
  332. Mediwin Pharmaceuticals
  333. Menadiona, S.L.
  334. Mercator Pharmaceutical Solutions
  335. Merch& Co.
  336. Meridian Life Science, Inc.
  337. Meridian Medicare Ltd.
  338. Mesoblast Limited
  339. Metrics Inc.
  340. MetrochemApi Private Limited
  341. Micro Labs Limited
  342. Microchem SRL
  343. Micro-Macinazione SA
  344. Micron technologies
  345. Micron Technologies Ltd
  346. Micro-Sphere SA
  347. Microtrol Sterilization Services Private Limited
  348. Mikart, Inc.
  349. Milda AG
  350. MiltenyiBiotec
  351. Minomic International Limited
  352. Mipharma Spa
  353. Mirror Pharmaceuticals LLC
  354. Mitovie Pharma
  355. Mnemosyne Pharmaceutical Inc.
  356. Molecular Partners
  357. MSD Chibret
  358. MSN Laboratories Private Limited 
  359. Multi Pack Solutions
  360. Mycenax
  361. Mylan Laboratories
  362. Nakoda Chemicals Limited
  363. Nanjing Pharmatechs Co., Ltd.
  364. Nascent Biologics
  365. Natco Pharma ltd.
  366. Nectar Lifesciences Limited
  367. Neos Therapeutics, LP
  368. Nephron Pharmaceuticals Corporation
  369. NerPharMaS.r.l.
  370. Neuland Laboratories Limited
  371. Nexgen Pharma, Inc.
  372. Nextar
  373. Ningbo Renjian Pharmaceutical Group 
  374. Niota Pharmaceuticals, Inc.
  375. Nippon Rika Co., Ltd.
  376. Nipro Patch Co., Ltd.
  377. Nitin Lifesciences Ltd.
  378. Nivon Specialities
  379. Norac Pharma
  380. Normaco
  381. North Star Processing, LLC.
  382. Norwegian Institute of Public Health
  383. Norwich Pharmaceuticals Inc.
  384. Novartis
  385. Novasep
  386. Novel Laboratories, Inc.
  387. Novozyme
  388. Nutragen Pharma Private Limited 
  389. Oakwood Laboratories, L.L.C.
  390. Oasis Laboratories Pvt. Ltd.
  391. Olainfarm
  392. Olon, SpA
  393. Oman Pharmaceutical Products Co. LLC.
  394. Omega Pharma
  395. Omnia Biologics
  396. OncoMed Pharmaceutical
  397. Oncotec Pharma Produktion GmbH
  398. Orchid Pharma
  399. OrexigenTherpeutics, Inc
  400. OrganicoFeinchemie GmbH Wolfen
  401. Orient Pharma 
  402. Orion Corporation 
  403. Orofino Pharmaceutical Group
  404. OSO Bio Pharmaceuticals Manufacturing, LLC
  405. Oxford BioTherapeutics
  406. PacificGMP
  407. Panacea Biotec Limited
  408. Par Pharmaceutical Inc.
  409. Parabolic Drugs
  410. Paragon Bioservices
  411. Pasteuria Bioscience
  412. Patheon (unit of DPx Holdings)
  413. PCAS Finland Oy (Subsidiary of PCAS S.A.)
  414. Pegasus farmaco India Pvt. Ltd.
  415. Pfanstiehl, Inc.
  416. Pfizer CentreSource
  417. Pharmaceutical Associates, Inc. (Subsidiary of Beach Products)
  418. Pharmaceutical Manufacturing Research Services, Inc.
  419. Pharmaceutics International, Inc.
  420. Pharmacyclics
  421. PharmAgra Labs
  422. Pharmanest AB
  423. Pharmasol Pharmaceuticals
  424. PharmaZell
  425. PharmedArtis GmbH
  426. Phyton Biotech LLC
  427. Piramal Pharma Solutions
  428. Pisgah Labs Inc
  429. Plasmid Factory
  430. PolyCarbon Industries, Inc.
  431. Polymun Scientific ImmunbiologischeForschung GmbH
  432. Polypeptide Laboratories Inc
  433. Porton Fine Chemicals Ltd.
  434. Powdersize, Inc
  435. PrimaPharm, Inc.
  436. ProBioGen AG
  437. Procaps Group
  438. ProcosS.p.A.
  439. Provizer Pharma
  440. PureTek Corporation
  441. PX' Therapeutics
  442. QS Pharma LLC
  443. Quality Chemical Laboratories
  444. Quay Pharmaceuticals Limited
  445. R L Fine Chem
  446. R.p. Scherer GmbH & Co. KG
  447. R5
  448. Rablon
  449. Radico Remedies
  450. Recipharm
  451. Redwig Pharma
  452. Regis Technologies Inc.
  453. Reliable Biopharmaceutical Corporation
  454. Reliance Life Sciences
  455. Reliance Life Sciences Private Limited
  456. Relthy Laboratories
  457. RentschlerBiotechnologie GmbH
  458. Richter Helm Biologics GmbH and Co KG
  459. RIVOPHARM SA
  460. Roche
  461. Rolabo Outsourcing, S.L.
  462. Rottendorf Pharma GmbH
  463. ROVI Contract Manufacturing 
  464. Rubicon Research Private Limited
  465. Rusan
  466. S.M. Pharmaceuticals
  467. SAFC Inc
  468. SAI Life Sciences
  469. Samsung Biologics
  470. Sandoz
  471. Sanico N.V.
  472. SanochemiaPharmazeutika AG
  473. Sanofi-Aventis
  474. Sanquin Pharmaceutical Servives
  475. Sartorius Stedium Biotech
  476. Sarvotham Care Ltd.
  477. SaviorLifetec Corporation 
  478. SCI Pharmtech Inc.
  479. Scil Proteins
  480. ScinoPharm Pharmaceuticals, Ltd.
  481. SellasLifeSciences Group
  482. Selvok Pharmaceutical Co.
  483. Sentiss Pharma
  484. Shandong Xinhua Pharmaceutical Company Limited
  485. Shanghai Pharmaceutical IMP. & EXP. Co., Ltd.
  486. ShangPharma
  487. Sharon Bio-Medicine 
  488. Shasun Pharmaceuticals Limited
  489. Shilpa Medicare Limited
  490. Siegfried
  491. Sigmapharm Laboratories, LLC
  492. Sirio Pharma
  493. SkyePharma
  494. Smruthi Organics 
  495. SMS Pharmaceuticals Limited
  496. SocietaItalianaMedicinaliScandicci (S.I.M.S.) Srl
  497. Softigel
  498. Solitaire Pharmacia Pvt. Ltd.
  499. Sonar Products
  500. Sovereign Pharmaceuticals, LLC
  501. SRS Pharmaceuticals Pvt. Ltd.
  502. Stason Pharmaceuticals, Inc.
  503. Statens Serum Institut
  504. Sterigenics U.S., LLC
  505. Suir Pharma
  506. Summit Biosciences Inc
  507. Sunrise Pharmaceutical Inc
  508. Surya Pharmaceuticals
  509. Suven Life Sciences Limited
  510. Swedish orphan Biovitrum AB
  511. Synbias Pharma
  512. SynCo Bio Partners
  513. Syncom Healthcare limited
  514. Syngene (Subsidiary of Biocon)
  515. Synthokem Labs Private Limited
  516. Synthonics Inc
  517. Tai Heng Industry Co., Ltd.
  518. Taj Pharamceuticals limited
  519. Tapemark Company
  520. TAPI
  521. Tedor Pharma Inc.
  522. The Ritedose Corporation
  523. Theon Pharmaceuticals
  524. Therapure Biopharma Inc.
  525. Tianjin Pharmaceutical
  526. Time Cap Laboratories
  527. Titan Pharma Pvt. Ltd.
  528. Tokyo Chemical Industry Co., Ltd.
  529. Tolmar
  530. Torrent Pharmaceuticals Limited
  531. Toyobo Biologics, Inc.
  532. TygerScientificInc.
  533. UCB
  534. Ultratab Laboratories, Inc.
  535. Ultratech India Ltd.
  536. Uman Pharma Inc.
  537. UMN Pharma Inc.
  538. Unibiotech Formulations
  539. Unichem Laboratories Limited
  540. Unimark Remedies Limited
  541. University of Nebraska - Biological Process Development Facility
  542. UPM Pharmaceuticals
  543. UQUIFA 
  544. US Pharma lab
  545. USV Limited
  546. Venturepharm Laboratories
  547. Vetcare
  548. Vetter Pharma
  549. VGXI Inc.
  550. Vibalogics
  551. Viropharm
  552. Vista Biologicals Corp.
  553. Visum Pharmaceutical Co., Ltd.
  554. Vital Health Care Pvt Ltd
  555. Vivante DMP Solutions
  556. VIVUS, Inc.
  557. VUAB Pharma 
  558. Wacker Biotech GmbH
  559. WaismanBiomanufacturing
  560. Wanbury Limited
  561. WellSpring Pharmaceutical Corp.
  562. West-ward Pharmaceutical Corp (Subsidiary of Hikma PLC)
  563. Wilmington PharmaTech
  564. Windlas Biotech ltd.
  565. Windlas Healthcare Private Limited
  566. Wintac Limited
  567. Wisdom Pharmaceutical Co., Ltd.
  568. Wockhardt Limited
  569. WRAIR Pilot Bioproduction Facility
  570. WuXiAppTec Co. LTD.
  571. Xcelience, LLC
  572. Xellia Pharmaceuticals 
  573. Xian Lijun Pharmaceutical 
  574. Xttrium Laboratories, Inc.
  575. Yaopharma Co., Ltd.
  576. Yash Pharma Laboratories Pvt. Ltd.
  577. Yung Zip Chemical
  578. Zen Labs
  579. Zenara
  580. ZhejianHisun Pharma
  581. Zhejian HISUN Pharmaceuticals Co.
  582. Zhejiang ApeloaJiayuan Pharmaceutical Co., Ltd.
  583. Zhejiang Changming Pharmaceutical Co., Ltd.
  584. Zhejiang Cheng Yi Pharmaceutical Co., Ltd
  585. Zhejiang Excel Pharmaceutical Co., Ltd.
  586. Zhejiang Huahai Pharmaceutical
  587. Zhejiang JianfengHaizhou Pharmaceutical Co. Ltd.
  588. Zhejiang Jiang Yuan Tang Botechnology Co., Ltd.
  589. Zhejiang Jingxin
  590. Zhejiang Shenzhou Pharmaceutical Co., Ltd.
  591. Zydus BSV Pharma Private Limited

PRICING DETAILS

USD 2,199

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com

This site uses cookies for better browsing experience  Accept

Copyright © 2023 Roots Analysis. All Rights Reserved.